← Back to Search

Kinase Inhibitor

BOS172738 for Non-Hematologic Cancers

Phase 1

Waitlist Available

Research Sponsored by Boston Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up a minimum of approximately 3 months

Awards & highlights

Study Summary

This trial will study the safety and if it is tolerated when given to patients with advanced solid tumors that have a RET gene alteration. They will also study what the maximum tolerated dose is.

Eligible Conditions

Advanced Non-Hematologic Cancers

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ a minimum of approximately 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~a minimum of approximately 3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and a minimum of approximately 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum tolerated dose (MTD) of BOS172738

Number of participants with any TEAE leading to study drug discontinuation

Number of participants with any non-serious TEAE

+4 more

Secondary outcome measures

Duration of Complete Response (DoCR)

Duration of Response (DoR)

Objective Disease Control Rate (ODCR)

+5 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: BOS172738Experimental Treatment1 Intervention

In Part A (dose escalation), participants with advanced solid tumors with rearranged during transfection (RET) gene alterations will receive oral BOS172738 at a starting dose of 10 milligrams (mg) once daily in each 28-day cycle. In Part B (dose expansion), participants with RET gene-fusion non-small cell lung cancer (NSCLC), with RET gene-mutant medullary thyroid cancer (MTC), and with RET gene-altered advanced tumors or NSCLC/MTC with prior specific RET gene-targeted therapy will be enrolled in Cohorts 1, 2, and 3, respectively, and will receive oral BOS172738 once daily in each 28-day cycle at the recommended Phase 2 dose (RP2D) established in Part A.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BOS172738

2018

Completed Phase 1

~120

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Boston PharmaceuticalsLead Sponsor

11 Previous Clinical Trials

743 Total Patients Enrolled

Media Library

BOS172738 (Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03780517 — Phase 1

Non-Hematologic Cancers Research Study Groups: BOS172738

Non-Hematologic Cancers Clinical Trial 2023: BOS172738 Highlights & Side Effects. Trial Name: NCT03780517 — Phase 1

BOS172738 (Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03780517 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies available for participants in this research trial?

"This clinical trial, initially posted in December 2018 and last modified on September 23rd 2022 is not currently recruiting participants. However, there are a plethora of other medical studies seeking enrolment at the present moment with 2,379 trials actively accepting patients."

Answered by AI

Has the governing body given their blessing to BOS172738?

"Our team at Power has attributed a rating of 1 to BOS172738's safety, as this is a Phase 1 trial and there are only limited amounts of data that prove the drug's efficacy."

Answered by AI

What is the breadth of sites where this study is being conducted?

"At present, the trial is being conducted at 4 different centres located in Gilbert, Philadelphia and Houston alongside other cities. To reduce travel needs, it's recommended to pick a clinic that's closest you geographically if you plan on taking part."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

2018. "Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03780517.